Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.1M Buy
8,029
+762
+10% +$195K 0.84% 23
2026
Q2
$1.83M Buy
7,267
+103
+1% +$22.2K 0.84% 29
2026
Q1
$1.56M Sell
7,164
-425
-6% -$94.3K 0.88% 23
2025
Q4
$1.73M Buy
+7,589
New +$1.73M 1.05% 23

Other funds holding ABBV

XXI Wealth's ABBV Position: Q3 2026 in Review

XXI Wealth increased its AbbVie (ABBV) stake by 10% in Q3 2026, buying an estimated $195K and bringing the position to 8,029 shares worth $2.1M. The position accounts for 0.84% of the portfolio, ranked #23.

XXI Wealth first reported a position in ABBV in Q4 2025 and has held it in 4 quarters since. 3,875 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

  • XXI Wealth held 8,029 shares of AbbVie worth $2.1M as of Q3 2026.
  • XXI Wealth bought 762 AbbVie shares in Q3 2026, an estimated $195K.
  • AbbVie made up 0.84% of XXI Wealth's portfolio in Q3 2026, its #23 holding.
  • XXI Wealth first reported a position in AbbVie in Q4 2025 and has held it in 4 quarters since.
  • 3,875 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on XXI Wealth's 13F filing for Q3 2026, filed 22 Oct 2026.